Q2765852 (Q2765852): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: import item from Greece) |
(Created claim: summary (P836): The company started its operations on 13/01/2014 having as its main activity “Cytological Laboratory Services” (CSD 86.90.15.06) and as a secondary to the “Medical Cytological Specialty Services” (CSD 86.22.19.14).This business plan includes a wide range of costs, which makes it an integrated investment proposal in the context of the operation of a fully equipped diagnostic cytological laboratory, which will outweigh competition. Operating expen...) |
||||||||||||||
| Property / summary | |||||||||||||||
The company started its operations on 13/01/2014 having as its main activity “Cytological Laboratory Services” (CSD 86.90.15.06) and as a secondary to the “Medical Cytological Specialty Services” (CSD 86.22.19.14).This business plan includes a wide range of costs, which makes it an integrated investment proposal in the context of the operation of a fully equipped diagnostic cytological laboratory, which will outweigh competition. Operating expenditure for two years:- Rent The cost of this category is EUR 5,280,00.2. Beneficiary’s insurance contributions. The insurance fund of the investment entity is EFKA (single social security institution). Its insurance contributions are estimated at EUR 5,425,08 for the 2 years of implementation of the project. According to the program guide, insurance contributions may not exceed 30 % of the total investment project.3. New job – Recruitment of a biologist for part-time (4 hours) employment The cost of this expenditure amounts to EUR 4,299,92.5. Purchase of cytological equipment.- Procurement of PCR- Hybridisation machine ProcurementThe cost of the above equipment is estimated at EUR 9,995,00 and is a necessary purchase for the upgrading and modernisation of the company.The total budget of the project amounts to 25.000.00EUR. The eligible budget is the same, i.e. EUR 25,000,00.The cytology laboratory at the time of submission of the supporting documents is the only laboratory in the whole area of its activity, having the obligation and the heavy workload to cover the cytological examinations of all the prefectures of this region. The main field of activity of the laboratory is the conduct of the Papanikolaou Test in order to intake gynecological cancer. To date, the laboratory has diagnosed some 40 cases of severe malformations which, if left undiagnosed, would lead to an equal number of uterine cancers. Note that in any such case the cost of treatment in a public hospital exceeds EUR 100,000,00, while the diagnosis cost in the case of Pap test does not exceed EUR 13!In recent years there has been considerable progress in the sensitivity of the detection of precancerous cervical lesions in the uterus by introducing DNA screening tests against human papilloma virus (HPV test). This test is performed in conjunction with the classic Pap tests, increasing sensitivity from 80 % to 99 %. The laboratory shall aim, with the support of the NSRF programme [Reinforcing the self-employment of tertiary education graduates (second cycle)] to undertake the purchase and immediate operation of the HPV Test method in order to fill the large gap currently existing in the area and contribute substantially to the early diagnosis and treatment of cervical cancer, with a view to contributing to the promotion of preventive medicine and to the reduction of hospital costs in the area. (English) | |||||||||||||||
| Property / summary: The company started its operations on 13/01/2014 having as its main activity “Cytological Laboratory Services” (CSD 86.90.15.06) and as a secondary to the “Medical Cytological Specialty Services” (CSD 86.22.19.14).This business plan includes a wide range of costs, which makes it an integrated investment proposal in the context of the operation of a fully equipped diagnostic cytological laboratory, which will outweigh competition. Operating expenditure for two years:- Rent The cost of this category is EUR 5,280,00.2. Beneficiary’s insurance contributions. The insurance fund of the investment entity is EFKA (single social security institution). Its insurance contributions are estimated at EUR 5,425,08 for the 2 years of implementation of the project. According to the program guide, insurance contributions may not exceed 30 % of the total investment project.3. New job – Recruitment of a biologist for part-time (4 hours) employment The cost of this expenditure amounts to EUR 4,299,92.5. Purchase of cytological equipment.- Procurement of PCR- Hybridisation machine ProcurementThe cost of the above equipment is estimated at EUR 9,995,00 and is a necessary purchase for the upgrading and modernisation of the company.The total budget of the project amounts to 25.000.00EUR. The eligible budget is the same, i.e. EUR 25,000,00.The cytology laboratory at the time of submission of the supporting documents is the only laboratory in the whole area of its activity, having the obligation and the heavy workload to cover the cytological examinations of all the prefectures of this region. The main field of activity of the laboratory is the conduct of the Papanikolaou Test in order to intake gynecological cancer. To date, the laboratory has diagnosed some 40 cases of severe malformations which, if left undiagnosed, would lead to an equal number of uterine cancers. Note that in any such case the cost of treatment in a public hospital exceeds EUR 100,000,00, while the diagnosis cost in the case of Pap test does not exceed EUR 13!In recent years there has been considerable progress in the sensitivity of the detection of precancerous cervical lesions in the uterus by introducing DNA screening tests against human papilloma virus (HPV test). This test is performed in conjunction with the classic Pap tests, increasing sensitivity from 80 % to 99 %. The laboratory shall aim, with the support of the NSRF programme [Reinforcing the self-employment of tertiary education graduates (second cycle)] to undertake the purchase and immediate operation of the HPV Test method in order to fill the large gap currently existing in the area and contribute substantially to the early diagnosis and treatment of cervical cancer, with a view to contributing to the promotion of preventive medicine and to the reduction of hospital costs in the area. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The company started its operations on 13/01/2014 having as its main activity “Cytological Laboratory Services” (CSD 86.90.15.06) and as a secondary to the “Medical Cytological Specialty Services” (CSD 86.22.19.14).This business plan includes a wide range of costs, which makes it an integrated investment proposal in the context of the operation of a fully equipped diagnostic cytological laboratory, which will outweigh competition. Operating expenditure for two years:- Rent The cost of this category is EUR 5,280,00.2. Beneficiary’s insurance contributions. The insurance fund of the investment entity is EFKA (single social security institution). Its insurance contributions are estimated at EUR 5,425,08 for the 2 years of implementation of the project. According to the program guide, insurance contributions may not exceed 30 % of the total investment project.3. New job – Recruitment of a biologist for part-time (4 hours) employment The cost of this expenditure amounts to EUR 4,299,92.5. Purchase of cytological equipment.- Procurement of PCR- Hybridisation machine ProcurementThe cost of the above equipment is estimated at EUR 9,995,00 and is a necessary purchase for the upgrading and modernisation of the company.The total budget of the project amounts to 25.000.00EUR. The eligible budget is the same, i.e. EUR 25,000,00.The cytology laboratory at the time of submission of the supporting documents is the only laboratory in the whole area of its activity, having the obligation and the heavy workload to cover the cytological examinations of all the prefectures of this region. The main field of activity of the laboratory is the conduct of the Papanikolaou Test in order to intake gynecological cancer. To date, the laboratory has diagnosed some 40 cases of severe malformations which, if left undiagnosed, would lead to an equal number of uterine cancers. Note that in any such case the cost of treatment in a public hospital exceeds EUR 100,000,00, while the diagnosis cost in the case of Pap test does not exceed EUR 13!In recent years there has been considerable progress in the sensitivity of the detection of precancerous cervical lesions in the uterus by introducing DNA screening tests against human papilloma virus (HPV test). This test is performed in conjunction with the classic Pap tests, increasing sensitivity from 80 % to 99 %. The laboratory shall aim, with the support of the NSRF programme [Reinforcing the self-employment of tertiary education graduates (second cycle)] to undertake the purchase and immediate operation of the HPV Test method in order to fill the large gap currently existing in the area and contribute substantially to the early diagnosis and treatment of cervical cancer, with a view to contributing to the promotion of preventive medicine and to the reduction of hospital costs in the area. (English) / qualifier | |||||||||||||||
point in time: 2 July 2021
| |||||||||||||||
Revision as of 12:22, 2 July 2021
Project Q2765852 in Greece
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q2765852 in Greece |
Statements
25,000.0 Euro
0 references
80.0 percent
0 references
26 March 2018
0 references
27 February 2021
0 references
ΜΥΓΔΑΚΟΣ,,ΝΙΚΟΛΑΟΣ,ΑΠΟΣΤΟΛΟΣ
0 references
40°21'14.47"N, 21°29'48.08"E
0 references
40°21'14.47"N, 21°29'48.08"E
0 references
Η επιχείρηση έκανε την έναρξη των εργασιών της στις 13/01/2014 έχοντας ως κύρια δραστηριότητα τις «Υπηρεσίες Κυτταρολογικού Εργαστηρίου» (ΚΑΔ 86.90.15.06) και ως δευτερεύουσα τις "Ιατρικές Υπηρεσίες Ειδικότητας Κυτταρολογίας" (ΚΑΔ 86.22.19.14).Το παρόν επιχειρηματικό σχέδιο περιλαμβάνει ένα ευρύ φάσμα δαπανών, γεγονός που το καθιστά μια ολοκληρωμένη επενδυτική πρόταση στα πλαίσια της λειτουργίας ενός πλήρους εξοπλισμένου διαγνωστικού κυτταρολογικού εργαστηρίου, το οποίο θα υπερτερεί έναντι του ανταγωνισμού.Συγκεκριμένα οι επενδυτικές δαπάνες αφορούν:1. Λειτουργικές δαπάνες για δύο έτη:- ΕνοίκιοΤο κόστος της δαπάνης αυτής της κατηγορίας ανέρχεται σε 5.280,00.2. Ασφαλιστικές εισφορές δικαιούχου. Το ασφαλιστικό ταμείο του φορέα της επένδυσης είναι ο ΕΦΚΑ (ενιαίος φορέας κοινωνικής ασφάλισης). Οι ασφαλιστικές του εισφορές υπολογίζονται σε 5.425,08 για τα 2 έτη υλοποίησης του έργου. Σύμφωνα με τον οδηγό του προγράμματος οι ασφαλιστικές εισφορές δεν μπορούν να υπερβαίνουν το 30% στο σύνολο του επενδυτικού σχεδίου.3. Νέα θέση εργασίας- Πρόσληψη ενός βιολόγου για μερική (4ωρη) απασχόλησηΤο κόστος της δαπάνης αυτής ανέρχεται σε 4.299,92.5. Αγορά εξοπλισμού κυτταρολογίας.- Προμήθεια μηχανήματος PCR- Προμήθεια μηχανήματος υβριδισμούΤο κόστος του παραπάνω εξοπλισμού υπολογίζεται στα 9.995,00 και αποτελεί αναγκαία αγορά για την αναβάθμιση και τον εκσυγχρονισμό της επιχείρησης.Ο συνολικός προϋπολογισμός του έργου ανέρχεται στις 25.000,00. Ο επιλέξιμος προϋπολογισμός είναι ο ίδιος, ήτοι 25.000,00.Το εργαστήριο κυτταρολογίας την στιγμή της υποβολής των δικαιολογητικών είναι το μόνο εργαστήριο σε όλη την περιοχή της περιφέρειας δραστηριοποίησης της, έχοντας την υποχρέωση και τον βαρύ φόρτο εργασίας να καλύψει τις κυτταρολογικές εξετάσεις όλων των νομών της εν λόγω περιφέρειας. Το κύριο πεδίο δραστηριότητας του εργαστηρίου είναι η διενέργεια του Τεστ Παπανικολάου με σκοπό την πρόσληψη του γυναικολογικού καρκίνου. Έως σήμερα το εργαστήριο έχει διαγνώσει 40 περίπου περιπτώσεις σοβαρών δυσπλασιών οι οποίες αν έμεναν αδιάγνωστες θα οδηγούσαν σε ισάριθμους καρκίνους της μήτρας. Σημειωτέων ότι για κάθε τέτοια περίπτωση το κόστος θεραπείας σε δημόσιο νοσοκομείο ξεπερνά τα 100.000,00, ενώ το κόστος διάγνωσης στην περίπτωση του τεστ Παπανικολάου δεν ξεπερνά τα 13 ευρώ!Τα τελευταία χρόνια έχει σημειωθεί αξιόλογη πρόοδος στην ευαισθησία της ανίχνευσης των προκαρκινικών αλλοιώσεων του τραχήλου της μήτρας με την εισαγωγή DNA τεστ ανίχνευσης έναντι ιού των ανθρωπίνων θηλωμάτων (HPV τεστ). Το τεστ αυτό γίνεται σε συνδυασμό με τα κλασικό τεστ κατά Παπανικολάου αυξάνοντας την ευαισθησία από το 80% στο 99%. Το εργαστήριο αποσκοπεί με την υποστήριξη του προγράμματος ΕΣΠΑ [Ενίσχυση της Αυτοαπασχόλησης Πτυχιούχων Τριτοβάθμιας Εκπαίδευσης (Β' Κύκλος)] να προβεί στην αγορά και στην άμεση επιχειρησιακή λειτουργία της μεθόδου HPV τεστ ώστε να καλύψει το μεγάλο κενό που υπάρχει σήμερα στην περιοχή και συμβάλει ουσιαστικά στην έγκαιρη διάγνωση και αντιμετώπιση του καρκίνου του τραχήλου της μήτρας συμβάλλοντας στην προαγωγή της προληπτικής ιατρικής και στην μείωση των νοσοκομειακών δαπανών στην περιοχή της περιφέρειας δραστηριοποίησης της.Το εργαστήριο σκοπεύει να εντάξει άμεσα το DNA HPV τεστ στις εξετάσεις που διενεργεί έχοντας δημιουργήσει ένα πλάνο υλικοτεχνικής υποδομής και επιπλέον σκοπεύει να προβεί στην πρόσληψη νέου επιστημονικού προσωπικού το οποίο θα απορροφήσει σημαντικό μέρος της επιδότησης που θα λάβει μέσω ΕΣΠΑ [Ενίσχυση της Αυτοαπασχόλησης Πτυχιούχων Τριτοβάθμιας Εκπαίδευσης (Β' Κύκλος)] συμβάλλοντας επίσης στην μείωση της ανεργίας.Η βιωσιμότητα του εγχειρήματος κρίνεται θετική λαμβάνοντας υπόψη τις ανάγκες της περιοχής, την ζήτηση που δημιουργήθηκε τελευταία για την εξέταση αυτή και για την μη διενέργεια της συγκεκριμένης εξέτασης από κανένα άλλο εργαστήριο του ιδιωτικού αλλά και του δημόσιου φορέα στην περιοχή, με αποτέλεσμα την εν τέλει μη εξέταση των ασθενών, αφού είναι δύσκολο να μεταβ (Greek)
0 references
The company started its operations on 13/01/2014 having as its main activity “Cytological Laboratory Services” (CSD 86.90.15.06) and as a secondary to the “Medical Cytological Specialty Services” (CSD 86.22.19.14).This business plan includes a wide range of costs, which makes it an integrated investment proposal in the context of the operation of a fully equipped diagnostic cytological laboratory, which will outweigh competition. Operating expenditure for two years:- Rent The cost of this category is EUR 5,280,00.2. Beneficiary’s insurance contributions. The insurance fund of the investment entity is EFKA (single social security institution). Its insurance contributions are estimated at EUR 5,425,08 for the 2 years of implementation of the project. According to the program guide, insurance contributions may not exceed 30 % of the total investment project.3. New job – Recruitment of a biologist for part-time (4 hours) employment The cost of this expenditure amounts to EUR 4,299,92.5. Purchase of cytological equipment.- Procurement of PCR- Hybridisation machine ProcurementThe cost of the above equipment is estimated at EUR 9,995,00 and is a necessary purchase for the upgrading and modernisation of the company.The total budget of the project amounts to 25.000.00EUR. The eligible budget is the same, i.e. EUR 25,000,00.The cytology laboratory at the time of submission of the supporting documents is the only laboratory in the whole area of its activity, having the obligation and the heavy workload to cover the cytological examinations of all the prefectures of this region. The main field of activity of the laboratory is the conduct of the Papanikolaou Test in order to intake gynecological cancer. To date, the laboratory has diagnosed some 40 cases of severe malformations which, if left undiagnosed, would lead to an equal number of uterine cancers. Note that in any such case the cost of treatment in a public hospital exceeds EUR 100,000,00, while the diagnosis cost in the case of Pap test does not exceed EUR 13!In recent years there has been considerable progress in the sensitivity of the detection of precancerous cervical lesions in the uterus by introducing DNA screening tests against human papilloma virus (HPV test). This test is performed in conjunction with the classic Pap tests, increasing sensitivity from 80 % to 99 %. The laboratory shall aim, with the support of the NSRF programme [Reinforcing the self-employment of tertiary education graduates (second cycle)] to undertake the purchase and immediate operation of the HPV Test method in order to fill the large gap currently existing in the area and contribute substantially to the early diagnosis and treatment of cervical cancer, with a view to contributing to the promotion of preventive medicine and to the reduction of hospital costs in the area. (English)
2 July 2021
0 references
Identifiers
5.033.975
0 references